Adapting Urology Practices in the Face of BCG Shortages
The impact of the BCG shortage on the treatment of bladder cancer, exploring various strategies adopted by urologists to optimize patient care. The conversation highlights the importance of risk stratification in deciding treatment protocols, considering factors like tumor size, location, multifocality, and histology, as well as patient age and overall health.
EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification
EP: 3.Adapting Urology Practices in the Face of BCG Shortages
EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage
EP: 5.Strategies for the Management of Recurrent Low-Grade Bladder Tumors
EP: 6.Navigating Treatment Options for Elderly Patients with High-Risk NMIBC
EP: 7.Investigational Novel Strategies in High-Risk BCG-Unresponsive NMIBC
EP: 8.Review of Cretostimogene Grenadenorepvec (CG) Clinical Trials in High-risk BCG-unresponsive NMIBC
EP: 9.Emerging Treatments High-Risk BCG-Unresponsive NMIBC setting
EP: 10.Treatment Strategies for BCG-Unresponsive NMIBC
EP: 11.Novel Approaches and Recent Trial Updates in Intermediate-risk NMIBC
EP: 12.Forward Looking NMIBC Treatment Advancements and Needs in 2024
This is a synopsis of the Viewpoints video series featuring moderator, Sam S. Chang, MD, MBA, from Vanderbilt University School of Medicine, and panelists Gary Steinberg, MD, FACS, from Rush University Medical Center, Mark Tyson, MD, of Mayo Clinic Phoenix, Roger Li, MD, from Moffitt Cancer Center, and Sandip M. Prasad, MD, MPhil, of Morristown Medical Center.
In Episode 3 delves into the challenges and adaptations in the treatment of bladder cancer due to Bacillus Calmette-Guérin (BCG) shortages. Dr. Mark Tyson discusses the impact of the BCG shortage on their practice, including adopting strategies like dose splitting and a 'five plus two' strategy for BCG induction and maintenance. The importance of risk stratification is emphasized to ensure that high-risk patients receive priority for BCG treatment. Dr. Tyson also cautions against altering the BCG regimen too much, referencing the phase 3 NIMBUS trial which indicated reduced efficacy with modified dosing schedules.
The discussion then moves to programmatic changes in response to the BCG shortage. Dr. Tyson explains how their practice transitioned to a comprehensive bladder cancer program with centralized BCG approval, ensuring that high-grade patients receive full-dose BCG. This shift has successfully managed BCG allocation even during shortages. Gary Steinberg, MD, FACS, highlights the importance of considering multiple factors in risk assessment and treatment planning, such as tumor size, location, multifocality, and histology, along with patient age and overall health. He expresses concern about treating non-muscle invasive tumors with aberrant histology, such as micropapillary or squamous differentiation, due to the lack of sufficient data on their treatment. Dr. Steinberg's approach emphasizes the necessity of not exacerbating the patient's condition with overly aggressive treatment.
This episode underscores the ongoing challenges in bladder cancer treatment due to BCG shortages and the necessity of adapting clinical practices. It highlights the importance of risk stratification, programmatic changes, and individualized patient care in optimizing treatment outcomes.
*Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
